Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Luminex Receives FDA and European Clearance for New Version of xTAG® CYP2D6 Kit

Published: Tuesday, July 16, 2013
Last Updated: Tuesday, July 16, 2013
Bookmark and Share
Luminex submits xTAG® CYP2C19 kit to FDA for review.

Luminex Corporation has announced that it has received U.S. FDA and European clearance for a new version of xTAG CYP2D6 Kit.

Additionally the company has submitted xTAG 2C19 Kit to FDA for review. Luminex is advancing its pharmacogenetic initiative for improved patient care.

"Test results that inform a physician on how a patient may react to a particular therapeutic are vital to improving patient care," said Patrick J. Balthrop, president and chief executive officer of Luminex.

Balthrop continued, "Pharmacogenetics is a fast-growing field and our flexible technology provides laboratories unique options to address their needs. Attaining FDA and CE clearance for xTAG CYP2D6 Kit demonstrates Luminex's commitment to offering diagnostics that optimize patient outcomes and lower overall health-care costs."

Cytochrome P450 2D6 (CYP2D6) is a clinically important gene that encodes a phase one drug metabolizing enzyme. CYP2D6 metabolizes greater than 25% of the drugs in use today including cardiovascular drugs, anti-psychotics, anti-depressants, pain-medications, β-blockers, anti-emetics, antiarrhythmics and anti-cancer drugs.

Variations in the CYP2D6 gene can result in distinct drug metabolizing phenotypes leading to sub-optimal drug responses, such as drug toxicity, adverse drug reactions (ADRs), or inadequate therapeutic effect.

An estimated 2.2 million serious ADRs occur yearly resulting in 100,000 deaths at a cost of $136 billion in the United States alone.

xTAG CYP2D6 Kit is an IVD assay that analyzes a patient's CYP2D6 genotype from DNA extracted from a blood sample to aid physicians in determining therapeutic strategy for drugs metabolized by the cytochrome P450 2D6 gene product.

The assay is run on the flexible Luminex® 100/200™ instrument. This new version of the kit optimizes performance on the *17 allele and features an updated software algorithm that detects all 17 genotypes that the assay is cleared for, including deletion and duplication genotypes.

Luminex has also submitted xTAG CYP2C19 Kit for FDA and CE-clearance. The CYP2C19 enzyme is responsible for metabolizing a variety of prodrugs and drugs used to treat ulcers, seizures, malaria and anxiety. It is also partially responsible for metabolizing drugs such as beta-blockers and some antidepressants.

Luminex will be featuring the new xTAG CYP2D6 Kit at the American Association of Clinical Chemistry (AACC) Annual Meeting & Clinical Lab, July 30 - Aug. 1 in Houston, TX, Booth #4539. Visit the Luminex booth for more information on Luminex's pharmacogenetic portfolio.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Luminex Technology Selected by Assurex Health
xTAG® Technology to aid in GeneSight® precision medicine test.
Saturday, March 21, 2015
Pioneering Human Protein Atlas Project Achieves a Major Milestone
Project leverages Luminex's xMAP® technology for biobank profiling research.
Thursday, March 20, 2014
Luminex Receives FDA and European Clearance for xTAG® CYP2C19 Kit
New cytochrome P450 2C19 assay helps physicians optimize individual patient care.
Tuesday, September 24, 2013
Merck and Luminex Corporation Enter Agreement
Collaboration to support patient selection for the clinical development of MK-8931, Merck’s lead investigational medicine for Alzheimer’s disease.
Thursday, July 04, 2013
Luminex Corporation and EMD Millipore Extend Their Global Supply and Distribution Agreement
This long-term agreement strengthens the partnership and facilitates development of life science and protein assays.
Thursday, May 30, 2013
Luminex Awarded $11 Million Contract by DTRA
Department of defense award accelerates development of Luminex bio-threat detection technology program.
Tuesday, August 14, 2012
Luminex Corporation Expands Life Science and Biodefense Groups
Two dedicated groups advance Luminex leadership in scientific research and public safety.
Thursday, April 26, 2012
Luminex and Partners HealthCare Announce Collaboration Agreement
Collaborative efforts aimed at translating biomarker discoveries into novel molecular diagnostic tests.
Wednesday, February 16, 2011
Luminex Corporation Launches New FDA Cleared Pharmacogenetic Diagnostic Test
xTAG® CYP2D6 kit can assist physicians in improving patient care by helping to determine a personalized therapeutic strategy.
Thursday, November 18, 2010
Luminex Corporation and ViroNovative Announce License Agreement for Human Metapneumovirus Rights
Luminex gains worldwide rights to use ViroNovative's human metapneumovirus intellectual property in the xTAG Respiratory Viral Panel.
Tuesday, July 15, 2008
Luminex Receives U.S. Food and Drug Administration Clearance for xTAG™ Respiratory Viral Panel
The Company has designed the test to simultaneously detect the most prevalent respiratory viruses.
Friday, January 04, 2008
Luminex Licenses Cystic Fibrosis Gene Patent from John Hopkins University
Luminex’s TAG-IT™ cystic fibrosis kits to include rights to university's proprietary genetic markers.
Tuesday, April 24, 2007
Luminex Hosts Planet xMAP Technology Symposium
The symposium includes presentations and workshops utilizing Luminex's xMAP® technology in clinical diagnostics and life sciences research.
Tuesday, April 25, 2006
Scientific News
Genetic Risk Factors of Disparate Diseases Share Similar Biological Underpinnings
Penn Institute for Biomedical Informatics and colleagues identify "roadmap" of disease mechanisms to identify candidate drug targets.
Genetic Markers Influence Addiction
Differences in vulnerability to cocaine addiction and relapse linked to both inherited traits and epigenetics, U-M researchers find.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
New Insights into Gene Regulation
Researchers have solved the three-dimensional structure of a gene repression complex that is known to play a role in cancer.
Controlling RNA in Living Cells
Modular, programmable proteins can be used to track or manipulate gene expression.
Genetic Approach May Lead to New Treatments for Digestive Diseases
Researchers at UMass Medical School have identified a new molecular pathway critical for maintaining the smooth muscle tone that allows the passage of materials through the digestive system.
Fructose Alters Hundreds of Brain Genes
UCLA scientists report that diet rich in omega-3 fatty acids can reverse the damage.
DNA Barcodes Gone Wild
A team of researchers at University of Toronto’s Donnelly Centre and Sinai Health System’s Lunenfeld-Tanenbaum Research Institute (LTRI) has developed a new technology that can stitch together DNA barcodes inside a cell to simultaneously search amongst millions of protein pairs for protein interactions.
New Genetic Risk Factors for Myopia Discovered
Genes and environment determine short-sightedness.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!